Scientists from US drugmaker MSD have found that the experimental drug Molnupiravir reduces the level of infectious virus in the early stages of the disease.
An experimental drug for the treatment of coronavirus is being tested in the United States, which has been shown to be highly effective at an early stage of the disease during testing.
- Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean
- Does This Mean We Stopped Being Animal and Started Being Human Due to ‘Copy Paste’ Errors?
- The One Lifestyle Choice That Could Reduce Your Heart Disease Risk By More Than 22%
- Aging: This Is What Happens Inside Your Body Right After Exercise
- Immune-Boosting Drink that Mimics Fasting to Reduce Fat – Scientists ‘Were Surprised’ By New Findings
It is reported that the drug molnupiravir showed a rapid decrease in the level of infectious virus in patients at an early stage of the disease.
The drug was tested in more than 200 hospitalized patients, all of whom had faster reductions in viral infectivity than those in the placebo group.
“We are very pleased to share our initial Phase 2 infectivity data at this important conference, which remains at the forefront for critical clinical scientific information in infectious diseases”
shared Dr. Wendy Painter, Chief Medical Officer of Ridgeback Biotherapeutics.
“At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data.”
Dr William Fischer, a leading researcher at the University of North Carolina School of Medicine, called the research results promising, but more research needs to confirm them.
“The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising and if supported by additional studies, could have important public health implications, particularly as the SARS-CoV-2 virus continues to spread and evolve globally”
noted Dr. William Fischer.
- Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean
- Does This Mean We Stopped Being Animal and Started Being Human Due to ‘Copy Paste’ Errors?
- The One Lifestyle Choice That Could Reduce Your Heart Disease Risk By More Than 22%
- Aging: This Is What Happens Inside Your Body Right After Exercise
- Immune-Boosting Drink that Mimics Fasting to Reduce Fat – Scientists ‘Were Surprised’ By New Findings
Molnupiravir is an experimental oral antiviral agent developed for the treatment of influenza.
